Trials / Active Not Recruiting
Active Not RecruitingNCT03932201
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 371 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Damoctocog alfa pegol (Jivi, Bay94-9027) | Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs. |
Timeline
- Start date
- 2019-10-21
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
- First posted
- 2019-04-30
- Last updated
- 2026-04-09
Locations
29 sites across 20 countries: United States, Belgium, Brazil, Canada, Colombia, Denmark, Germany, Greece, Italy, Japan, Kuwait, Netherlands, Norway, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates
Source: ClinicalTrials.gov record NCT03932201. Inclusion in this directory is not an endorsement.